Jan 30, 2026
What is the regulatory and approval status of karylef worldwide as of 2025?
oral XPO1 inhibitor (branded XPOVIO , NEXPOVIO in some markets) is an approved oncology medicine across three indications and has secured regulatory and reimbursement wins in dozens of ex‑U.S. territo...